FDA orders a rare vision-loss warning on all GLP-1 drugs, including Mounjaro and Wegovy
_Image credit: Euronews_
The US FDA will require every GLP-1 medicine, from Ozempic and Wegovy to Mounjaro, Zepbound and Foundayo, to carry a label warning about NAION, a rare eye condition that can cause sudden, permanent vision loss in one eye. Its review of 126 trials with more than 134,000 patients, plus real-world data, found a potential increased risk that it judged warranted a class-wide warning. Europe's EMA already lists NAION as a very rare side effect of semaglutide, and anyone with sudden blurred vision or blind spots should get medical advice straight away.
Source: Euronews (9 Nov 2026). Image: Euronews.